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Abstract
Purpose/Objective(s): Despite strong interest in combining stereotactic ablative radiotherapy 
(SAR) with immunotherapy, limited data characterize the systemic immune response following 
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SAR. We hypothesized that the systemic immune response to SAR differs by irradiated site due to 
inherent differences in the microenvironment of various organs.
Materials/Methods: Patients receiving SAR to any organ underwent prospective blood banking 
pre- and 1–2 weeks post-SAR. Peripheral blood mononuclear cells (PBMC) and serum were 
isolated. PBMC were stained with fluorophore-conjugated antibodies against T and natural killer 
(NK) cell markers. Cells were interrogated by flow cytometry and results were analyzed using 
Flow Jo software. Serum cytokine and chemokine levels were measured using Luminex. We 
analyzed changes from pre- to posttherapy with paired t-tests or 1-way ANOVA with Bonferroni’s 
post-test.
Results: Thirty-one patients had evaluable PBMC for flow cytometry and thirty-seven had 
evaluable serum samples for Luminex analysis. Total NK cells and cytotoxic (CD56dim CD16+) 
NK cells decreased (p = 0.02) and TIM3+ NK cells increased (p = 0.04) following SAR to 
parenchymal sites (lung and liver), but not to bone or brain. Total memory CD4+ T cells, activated 
(ICOS+) and CD25+ CD4+ memory T-cells, and activated CD25+ CD8+ memory T cells 
increased following SAR to parenchymal sites, but not bone or brain. Circulating levels of TNF-α 
(p = 0.04) and multiple chemokines, including RANTES (p = 0.04), decreased after SAR to 
parenchymal sites, but not bone or brain.
Conclusions: Our data suggest SAR to parenchymal sites induces systemic immune changes, 
including a decrease in total and cytotoxic NK cells, an increase in TIM-3+ NK cells, and an 
increase in activated memory CD4+ and CD8+ T cells. SAR to non-parenchymal sites did not 
induce these changes. By comparing the immune response after radiation to different organs, our 
data suggest SAR induces systemic immunologic changes dependent upon irradiated site.
SUMMARY
We performed a prospective study to assess the systemic immune response 1–2 weeks following 
stereotactic radiation (SAR) to different organs using flow cytometry for immunophenotyping and 
Luminex analysis. Our results suggest SAR to parenchymal sites (lung and liver) induces systemic 
immune changes, including a decrease in total and cytotoxic NK cells and an increase in TIM-3+ 
NK cells and activated memory CD4+ and CD8+ T cells. SAR to non-parenchymal sites did not 
induce these changes.
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INTRODUCTION:
Stereotactic ablative radiotherapy (SAR), a technique for delivering ablative doses of 
conformal radiotherapy over 1–5 fractions, has emerged as a standard treatment option for a 
variety of solid tumors, both for definitive therapy of localized disease and for local control 
of metastatic sites.1,2,3,4,5,6,7 Recently, there has been considerable interest in combining 
radiotherapy with immunotherapy in order to use radiation as an in situ tumor vaccine that 
enhances the efficacy of immunotherapy.8,9,10,11,12 While there are many registered, actively 
accruing clinical trials that incorporate radiation with immune checkpoint inhibitors,13,14 it 
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is unclear how to optimize radiotherapy in these trials because there is insufficient data 
investigating the immune response to SAR alone.
The immunomodulatory effects of radiotherapy, particularly local immune effects on the 
tumor microenvironment, are well-established in preclinical models,8,15 and include 
induction of immunogenic cell death,16,17 release of antigens for T cell priming,18 improved 
T cell homing to tumor sites,19 shift in the polarization of tumor associated macrophages,19 
and destruction of immunosuppressive stromal cells in the tumor microenvironment,20 
amongst others. More recent studies suggest that hypofractionated radiation schedules 
produce very different biologic effects than traditional conventionally fractionated radiation.
21,22,23,24
 Clinical reports of distant, or “abscopal” responses in patients have described 
systemic immunophenotype changes, but all of these reports have been in the setting of 
combined radiation and immunotherapy.25,26,27 Several small studies have investigated the 
immune response to SAR for early stage lung cancer,28,29 and more recently additional 
studies have investigated components of the immune response after SAR for hepatocellular 
carcinoma,30 pancreatic cancer31 and breast cancer.32 However, we know of no published 
studies that directly compare changes in systemic immunophenotype and cytokine 
signatures following SAR without systemic therapy to different irradiated sites. Investigating 
differences in systemic immunophenotype after SAR based on irradiated site could be 
critical for the rational design of future combined SAR + immunotherapy trials.
There are well-defined, inherent differences in the immune microenvironment of different 
organs, from the relatively immunoprivileged brain protected by the blood-brain barrier, and 
immunoprivileged hematopoietic stem cell niche in the bone marrow, to the immunotolerant 
lung and liver, which are constantly exposed to antigens.33,34,35 As natural killer (NK) cells 
comprise a large portion of the immunotolerant organs such as the lung and liver, we 
hypothesized that radiation to these sites may cause unique changes in specific NK cell 
populations.33,36 We hypothesized that the systemic immune response to SAR would differ 
based on irradiated site, and set out to gain a comprehensive understanding of these 
differences to refine future clinical trials combining radiotherapy and immunotherapy. We 
prospectively collected blood samples prior to SAR and 1–2 weeks post-SAR from patients 
undergoing SAR to lung, liver, bone, or brain to measure changes in markers of the systemic 
immune response, such as cytokine/chemokine signatures and immunophenotype changes in 
peripheral blood mononucleated cells (PBMCs).
MATERIALS & METHODS:
PATIENTS
Patients were recruited as part of an Institutional Review Board-approved blood collection 
protocol at XXXXX, designed to assess the systemic immune response following SAR. 
Patients seen in the radiation oncology clinic in consultation for SAR were recruited by 
study team investigators. Eligible patients were scheduled to undergo 1–5 fractions of 
stereotactic body radiation therapy (SBRT) or 1–10 fractions of hypofractionated conformal 
radiotherapy for cancer of any histology and site (including the lung, liver, adrenal, brain, or 
bone, and other organs) per standard-of-care treatment. Patients under the age of 18 and 
those unable to provide informed consent were ineligible. No specific eligibility criteria with 
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regards to concurrent or prior systemic therapy were used. Blood samples were obtained by 
venipuncture prior to radiation treatment, either at the time of consultation, at simulation, or 
on the first day of treatment prior to delivery of the first fraction, and 7–14 days after 
radiation. Approximately 30 ml of blood was collected during each blood draw in10 ml 
vacutainer blood collection tubes with and without EDTA (for PBMC and serum, 
respectively) (Becton Dickinson, Franklin Lakes, New Jersey). All blood samples were de-
identified before processing of serum and PBMC.
BLOOD PROCESSING AND STORAGE
Whole blood was centrifuged at 1400 rpm for 15 minutes at room temperature. Serum and 
plasma were aliquoted into cryovials to be frozen at −80°C. Mononuclear cells were isolated 
via Ficoll-Paque gradient (BD Biosciences). This was centrifuged at 1400 rpm for 5 min at 
room temp. After RBC lysis, the PBMC were counted for viability and re-suspended in 
freezing medium (50% IMDM, 40% fetal bovine serum and 10% DMSO) at a concentration 
of at 1 to 10 × 106 cells/mL. Cells were aliquoted into cryogenic vials and stored at −80°C in 
the XXXX, where testing was performed by study personnel.
LUMINEX ANALYSIS
Luminex bead-based assays (BioRad, Hercules, CA, USA) were performed on serum 
specimens from 37 patients to measure circulating levels of 19 cytokines and 11 chemokines 
(Appendix 1) according to manufacturer’s instructions. Most cytokines were assessed using 
the Cytokine 17-plex assay (M5000031YV), but Cytokine IFN-α2 (171B6010M) was 
measured using cytokine group II standards (171D6001). TGF-β isoforms 1, 2, and 3 were 
measured using the TGFβ−1, 2, 3, kit (TGFBNAG-64K-03) (EMD Millpore, Billerica, MA). 
The majority of the chemokines were measured using the chemokine standard 171DK0001, 
while RANTES was measured with standard 171B5025M. Concentrations were calculated 
using a five-parameter standard curve. Serum samples were assayed in duplicate, and 
averaged to calculate final concentrations.
FLOW CYTOMETRY
PBMC were thawed rapidly in a 37°C water bath and diluted into RF10 media (RPMI 1640 
media (ThermoFischer Scientific, USA) with 10% fetal bovine serum and 1% Penicillin/
Streptomycin (Sigma-Aldrich). Cell number and viability were determined using trypan blue 
exclusion with a hemocytometer after thawing. PBMCs from 30 patients were available for 
flow cytometry analysis. Immunophenotyping of PBMCs was performed using two panels 
of antibodies, one panel to characterize NK cells and one to characterize T cells.37,38 All 
fluorochrome-conjugated antibodies (Appendix 2) were from BioLegend (San Diego, CA, 
USA), unless otherwise indicated. Cells were incubated with antibodies diluted in staining 
buffer (PBS containing 1% human serum and 1% Pen/Strep) at 4°C in the dark for 20 
minutes. Cells stained with the NK panel were washed, centrifuged, resuspended in staining 
buffer, and stored at 4°C. Cells stained with the T cell panel were washed, fixed with Fix/
Perm Buffer (eBiosciences, San Diego, CA, USA) for 30 minutes at 4°C. After washing, 
cells were resuspended in Perm/Wash buffer containing anti-Foxp3 antibody or isotype 
control for 30 minutes in the dark at room temperature before being washed and 
resuspended in staining buffer. Phenotype analysis was done by gating 50,000 to 200,000 
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cells according to FCS/SSC with a LSR Fortessa flow cytometer using DIVA version6 
software (BD Biosciences, San Diego, CA, USA). Data were analyzed using Flow Jo 
software (Flow Jo LLC, Ashland, OR, USA). Positive and negative cell populations for each 
marker were determined using fluorescence minus one (FMO) controls39 and unstained cells 
were used as a negative control. Instrument settings were verified and adjusted with the mid-
peak bead of the 8-peak calibration bead set (Spherotech) before each acquisition session. 
Compensation beads (BD Biosciences) were used to correct for spectral overlap between 
channels.
STATISTICAL ANALYSIS
Statistical analyses were carried out using Graph Pad Prism Software (Graph Pad, La Jolla, 
CA, USA) and R (Vienna, Austria). Baseline characteristics between subgroups were 
compared using Chi-square tests and one-way analysis of variance (ANOVA). Changes for 
each parameter across the entire cohort were assessed using paired t-tests. To explore 
differential response across treatment sites, lung and liver lesions were combined into one 
cohort called “parenchymal” sites. Differences in immunophenotype changes and cytokine/
chemokine response between parenchymal sites and bone and brain sites were analyzed 
using one-way analysis of variance (ANOVA) with Bonferroni’s post-test for continuous 
variables to account for multiple comparisons. Chi-square tests were used to identify 
significant variation across subgroups. Data are presented in bar graphs with vertical bars 
indicating the mean and lines representing standard error of the mean (SEM). Spearman 
correlation coefficients were computed for changes in each immune cell population with 
radiation–associated variables including total dose, dose per fraction and size in cubic 
centimeters of the planning target volume (PTV). For all tests, statistical significance was 
assessed at the 0.05 level (2-sided).
RESULTS:
Patient Characteristics
Patients scheduled to undergo SAR to any organ for a primary or metastatic solid tumor 
prospectively enrolled onto an institutional blood banking protocol between August 2014-
June 2017. A total of 40 patients were included in the analysis, 31 enrolled patients had 
evaluable PBMC samples from pre-SAR and 7–14 days post-SAR, and 37 enrolled patients 
had pre- and post-treatment serum samples suitable for Luminex analysis of cytokines and 
chemokines. Of these 40 total patients included in either analysis, 22 (54%) underwent SAR 
for a lung tumor, 4 (9.8%) underwent SAR to a liver tumor, 9 (22.0%) underwent SAR to a 
bone lesion, 5 (12.2%) underwent SAR to the brain. One patient (2.4%) was treated to both 
a lung tumor and soft tissue tumor simultaneously.
Baseline patient characteristics for all patients included in immunophenotyping or Luminex 
analysis are shown in Table 1. Median age was 68 years (range: 37–86), with 23 men (58%) 
and 17 women (42%). A non-significant trend toward older median age and greater pack-
years smoking history was noted for patients treated to parenchymal sites as compared to 
brain or bone. Forty-one percent of patients treated to parenchymal sites had received at least 
one prior course of chemotherapy in their lifetime, as compared to 60–66% of patients 
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treated to bone or brain (p=0.35). No enrolled patients were receiving systemic dose steroids 
or concurrent infusional chemotherapy or immunotherapy at the time of SBRT. Seven 
patients were receiving other cancer-directed systemic therapy at the time of SAR, including 
androgen deprivation (n=1), endocrine therapy (n=2), tyrosine kinase inhibitor (n=3), and 
oral capcitabine (n=1). Twenty-four patients had not received cancer-directed systemic 
therapy within the past year. Among the remaining 9 patients who had received systemic 
therapy within the past year, the median time from last systemic therapy was 74 days (range: 
14–254 days). The median PTV volume was 29.4cc (range, 5.5–118.1) for parenchymal 
lesions, 48.9cc (11.5–137) for bone lesions and 0.84cc (range, 0.06 −2.08) for brain lesions 
(p=0.13). The parenchymal group received a median dose of 50 Gy (range, 35–54 Gy) over 
3–5 fractions, while the bone group received a median dose of 24 Gy (range, 24–27 Gy) over 
3 fractions, and the brain group received a median of 21 Gy (range, 20–21 Gy) in a single 
fraction (p<0.001). However, the groups were similar in terms of other patient 
characteristics, as shown in Table 1.
Changes in Natural Killer cells in the Periphery after SAR to Parenchymal Sites
PBMCs from 31 patients were available for flow cytometry analysis. Surface staining of NK 
cell markers was used in the gating strategy to identify NK cell subsets shown in Figure 1A. 
There was a statistically significant decrease in the percentage of total NK cells after SAR to 
parenchymal sites (20.49 +/− 2.36 versus 16.76 +/− 2.436; p=0.01) (Figure 1B and 
Supplemental Figure 1A). In addition, there was a significant decrease in the percentage of 
cytotoxic CD56dim CD16+ NK cells after SAR to parenchymal sites (17.58 +/−2.34 versus 
13.17+/−2.052; p=0.024) (Figure 1C). No significant change was identified in the 
percentage of cytokine-producing CD56high CD16neg NK cells in the periphery for any 
patient cohort. There was no statistically significant change in the percentage of total NK 
cells, cytotoxic NK cells or cytokine-producing NK cells after SAR to the bone or brain 
(Figure 1B and Supplemental Figure 1B and 1C). In addition, we identified a statistically 
significant increase in the percentage of TIM-3+ NK cells in the peripheral blood after SAR 
to parenchymal sites (15.84+/−3.165 versus 19.65+/−3.261; p = 0.039), but not following 
SAR to the bone or brain (Figure 2). No statistically significant difference was identified in 
PD-1 expression on any NK cell subset after SAR (data not shown).
Increase in Activated Memory CD4+ and CD8+ T cells after SAR to Parenchymal sites
Human naïve and memory T cells are distinguished by CD45RA and CD45RO reciprocal 
isoforms, 40 and central and effector memory T cell subsets are identified based on the 
expression of CD45R isoforms and either of the homing molecules, CCR7 or CD62L.41 In 
this study, we designated CD45RA− CD62L+ T cells to represent central memory T cells 
(which home to the lymph nodes) and CD45RA− CD62L- cells to represent effector 
memory T cells which carry out effector functions in the tissue.41 (Figure 3A) There was a 
statistically significant increase in the percentage of total CD4+ memory T cells in the 
PBMC after SAR to parenchymal sites (29.68+/−2.65 versus 38.75+/−3.46; p = 0.026) 
(Figure 3B and Supplemental Figure 2A), but not after SAR to the bone or brain (Figure 3B 
and Supplemental Figure 2B and 2C).
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Our analysis of the effector and central memory CD4+ T cell compartments focused on the 
expression of the activation markers, CD25 and ICOS, on memory T cell subsets (Figure 3C 
and 3D). We identified an increase in the percentage of activated CD4+ memory T cells after 
SAR as demonstrated by a marked increase in the percentage of ICOS+ CD4+ T cells of 
total lymphocytes (0.8813+/−0.19 versus 1.739+/−0.241; p = 0.0005) (Figure 3C) and about 
a two-fold increase in the percentage of activated CD25+ CD4+ T cells after SAR (1.414+/
−0.42 versus 2.97+/−0.60; p = 0.078). (Figure 3D). None of these changes were seen after 
SAR to the bone or brain (Figure 3C and Figure 3D). No change in PD-1 expression was 
seen in the on the memory CD4+ T cell population after SAR to any site (Supplemental 
Figure 3). In addition, the percent of CD25+ Foxp3+ CD4+ regulatory T cells did not 
change after SAR to any site (Supplemental Figure 4).
Analysis of CD8+ memory T cells showed no difference in percent of total CD8+ T cells 
after SAR (Figure 4A), but did show a strong trend toward an increase in the percentage of 
activated CD25+ CD8+ memory T cells after SAR to parenchymal sites (1.388+/−0.49 
versus 3.50+/−1.10; p = 0.058) (Figure 4B). There were no changes in CD8+ memory T cell 
populations after SAR to the bone or brain.
Effect of Total Dose, Dose per Fraction, and Planning Target Volume on Immune Cell 
Populations
Total dose was positively associated with change in % ICOS+ CD4+ memory T cells 
(Spearman correlation coefficient (r) =0.46, p=0.022) and change in % CD25+ CD8+ 
memory T cells (r=0.57, p=0.006). The dose per fraction was not associated with any 
changes in immune cell populations. (Supplemental Table 1). Size of the PTV was positively 
associated with change in % ICOS+ CD4+ memory T cells (r=0.43, p =0.031) and change in 
%T regulatory cells (r=0.43, p=0.031). In addition, PTV size was also associated with 
change in % TIM−3+ NK cells (r=0.48, p=0.008) (Supplemental Table 1).
Changes in Cytokine and Chemokines after SAR to Parenchymal Sites
Serum specimens from 37 patients were evaluable for Luminex analysis. We measured 
circulating levels of 19 cytokines and 11 chemokines (Appendix 1). Those cytokines and 
chemokines with >75% of values below the lowest limit of detection (LLOD) were excluded 
from this analysis. Therefore, the final Luminex analysis included 15 evaluable markers 
(IL-2, IL-4, IL-6, IL-12, TGF-β1, TGF-β2, TNF-α, IP-10, RANTES, MIP-1α, MIP-1β, 
MCP-1, MCP-2, and SCYB16). There was a systemic decrease in TNF-α (23.10+/
−1.97versus 19.54+/−1.797; p = 0.042), and the chemokines IP-10 (459.4+/−79.76 versus 
347.8+/− 44.75; p = 0.048), MCP1 (14.4+/−0.96 versus 11.55+/−1.00; p = 0.0098), MCP2 
(172.5+/−18.54 versus 138.6+/−12.43; p = 0.007), MIP-1α (18.67+/−1.49 versus 16.33+/
−1.32; p = 0.024), and RANTES (9028+/−864.8 versus 6759+/−485.3; p = 0.035) following 
SAR to parenchymal sites (Figure 4). Bonferroni correction was used to correct for multiple 
hypothesis testing. No significant cytokine changes were observed after SAR to the bone or 
brain (Figure 4). No changes in the pro-inflammatory cytokines IFN-α, IFN-γ or TGF-β 
were identified.
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DISCUSSION:
Due to widespread interest in combining radiation with immunotherapy, there are numerous 
actively accruing clinical trials are underway that combine SAR with immune checkpoint 
inhibitors. The scientific rationale for these clinical trials is based on preclinical studies 
suggesting that radiation can serve as an in situ vaccine to augment the effects of 
immunotherapy, as well as a handful of case reports showing impressive clinical responses 
to such combinations. However, limited preclinical or clinical data are available to guide the 
selection of radiation dose, fractionation and site in order to optimally synergize with 
immunotherapy. We initiated this prospective specimen banking study with a goal of refining 
our understanding the systemic immune response to SAR monotherapy, and how response 
differs based on the site irradiated. To our knowledge, no prior studies in patients have 
directly compared the systemic immune response in patients following SAR to different 
organs.
There are a few key studies characterizing immune changes following SAR in the setting of 
concurrent immunotherapy. Tang et al. reported that patients who received liver-directed 
SAR in conjunction with the CTLA-4 inhibitor ipilimumab had enhanced peripheral T-cell 
activation (GITR+ or LAG3+ CD8+ T-cells) compared with patients that underwent lung-
directed SAR.42 Hiniker et al identified an increase in peripheral IL-2-producing CD8+ T-
cells and central memory T-cells after radiation in a patient with a complete response to 
CTLA-4 inhibition and liver-directed SAR.26 Postow et al report detailed immunoprofiling 
on a patient with progressive melanoma on CTLA-4 blockade who subsequently developed a 
systemic response following palliative radiotherapy, and noted an increase in ICOS+CD4+T 
cells, NY-ESO-1 specific IFN-gamma producing CD4+ T cells, and HLA-DR
+CD14+monocytes, as well as a decrease in MDSCs.25
In addition, there are published reports of the systemic immunophenotype in patients with 
Stage I or II NSCLC who received SAR alone. Maehata et al described peripheral immune 
changes that occur following stereotactic body radiotherapy (SBRT) for stage I non-small 
cell lung cancer (NSCLC), showing that SBRT induces lymphopenia and decreased NK cell 
activity, which they attribute to radiation directed to vertebral bone marrow in the SBRT 
field.28 Trovo et al characterized cytokine changes following SBRT versus conventional 
radiation for early stage NSCLC, and found a mean reduction of IL-10 and IL-17 plasma 
levels, but did not look at individual immune cell subsets.29 Rutkowski et al studied immune 
cell types after SBRT and observed an increase in the proportion of total CD8+ T cells, total 
CD4+ T cells, and CD4+ T cells expressing GATA-3, T-bet or ROR-γt, as well as a decrease 
in CD4+ Foxp3+ regulatory T cells,43 however this study did not evaluate NK cells. All of 
these studies examine the immune phenotype after SBRT to the lung alone. To our 
knowledge, there have been no studies directly comparing the peripheral immune response 
after SAR to different organs in the absence of concurrent immunotherapy.
We hypothesized that differences in T cell and NK cell activation following radiotherapy to 
different sites may relate to differences in the degree and potency of immunosuppression of 
the target tissue. There has been some proof this phenomenon in pre-clinical studies that 
have shown that intracranial melanoma produces more functional exhaustion and 
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impairment of T cell effector function than subcutaneous disease with the same tumor 
histology.44 To address this question, we focused on the unique tissue microenvironments 
that characterize the brain, bone, lung, and liver. The brain is characterized by the blood 
brain barrier (BBB), which sequesters lymphocytes during steady state creating a relatively 
“immunoprivileged site,” but allows lymphocytes to transverse the cerebral vasculature 
during pathologic states.45 The bone marrow contains the perivascular hematopoietic stem 
cell (HSC) niche, which contains mesenchymal stem cells and is characterized by hypoxia, 
as well as osteoclasts, involved in bone reabsorption, and osteoblasts involved in bone 
remodeling.35,46,47,48 In contrast, the lung is in constant contact with toxins and pathogens 
from the environment during respiration, and bronchial epithelial cells interact with innate 
immune cells including plasmacytoid dendritic cells, alveolar macrophages, and NK cells, 
which promote immune tolerance.49 Similarly, the liver is constantly exposed to antigens 
transported from the colon via the portal vein, and therefore is composed of an abundance of 
innate immune cells, such as NK cells, γδ T cells, and Kupffer cells, which also contribute 
to immune tolerance.33 Both the lung and liver develop immune tolerance to the majority of 
the antigenic load delivered via air exchange or the portal venous blood supply.” 33,50 Given 
the differences in blood supply, antigenic load, and relative abundance of innate immune 
cells and lymphocytes between these organs, we hypothesized that SAR delivered to these 
immunotolerant organs would differ from that of immunoprivileged organs such as the brain.
Due to the abundance of NK cells in the lung and liver, we hypothesized that these innate 
immune cells may play a role in the response to SAR in these organs. While NK cells do not 
express antigen receptors, they play important roles in viral infections and anti-tumor 
immunity by cytotoxic killing or the release of IFN-gamma. In humans, two populations of 
NK cells can be distinguished on the basis of CD56 expression.51,52 CD56dim cells that 
express CD16 (the low-affinity receptor for immunoglobulin G, FcRγIII) have enhanced 
cytotoxicity, while CD56hi NK cells that do not express CD16 (CD56hi CD16− cells) are 
able to secrete large amounts of IFN-γ, GM-CSF and TNF-α.53 Our results show a decrease 
in both total NK cells and cytotoxic NK cells after SAR to these parenchymal sites. The 
decrease in NK cells in the peripheral blood after SAR to parenchymal organs could 
represent increased homing or migration of NK cells to the irradiated tumor site. Previous 
work in our lab using a patient-derived xenograft model demonstrates decreased tumor 
volume and increased survival of PDX-bearing mice treated with a combination of radiation 
and autologous NK cell adoptive therapy.54 Tumor irradiation in this model leads to tumor 
cell upregulation of stress ligands such as NKG2D that activate NK cells, and increase 
homing and infiltration of tagged NK cells into tumor.54 These findings suggest that the 
decrease in systemic NK cells after SAR identified in the current study may be secondary to 
increased NK cell homing to the tumor site. However, we cannot exclude the possibility that 
the decrease in NK cells seen in the peripheral blood of patients in our study may represent a 
systemic depletion of NK cells from both the irradiated organs and the peripheral blood.
TIM-3 (T-cell Immunoglobulin- and Mucin-domain-containing molecule-3) was initially 
identified as a T-helper 1-specific protein involved in regulating T-cell responses, but the 
highest expression of TIM-3 is found on human NK cells. We saw an increase in circulating 
TIM-3+ NK cells after SAR to parenchymal sites. Previous studies on TIM-3+ NK cells 
have focused on their role as exhausted NK cells in several cancers, including melanoma and 
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colorectal cancer.55,56 While prior studies have shown that the presence of these cells is 
associated with worse responses to therapies such as surgery,56 TIM-3+ NK cells have never 
been linked to radiation. In aggregate, our data shows that there is a decrease in NK cells in 
the periphery following SAR but an increase in the TIM-3+ NK cell subset. Future studies 
will examine the mechanism by which SAR induces NK cell exhaustion and whether anti-
TIM-3 antibodies could be used to reverse NK cell exhaustion after radiation.
Given the importance of memory T cells in the induction of the “abscopal” response, we 
investigated the role of SAR in the induction of memory T cell response. We found an 
increase in CD4+ memory T cells after SAR to parenchymal sites, with increased expression 
of ICOS and CD25 activation markers on these cells. Inducible Co-stimulator (ICOS) is a T-
cell specific cell surface activation and co-stimulatory molecule structurally related to CD28 
and CTLA-4 that increases the proliferation and survival of activated CD4+ effector memory 
T cells.42 Anti-CTLA-4 therapy (ipilimumab) increases the frequency of CD4+ T cells 
expressing ICOS, and these effector T cells produce IFN-gamma.57 This is due to increased 
signaling through the phosphinositide-3-kinase (PI3K) pathway and an increase in the 
expression of T-bet.58 An increased frequency of ICOS+ CD4+ T cells is associated with 
improved clinical outcomes for anti-CTLA-4 and anti-OX40 immunotherapies.57,59 
Importantly, this population is not induced by anti-PD-L1 therapy, and may represent a 
distinct mechanistic pathway of anti-tumor immunity.60 Our recent clinical data presented 
here demonstrates that this cell population is also upregulated after SBRT. Therefore, it is 
possible that activation of ICOS+CD4+ T cells may represent a novel, but synergistic 
immune mechanism whereby SBRT could enhance PD-L1 checkpoint inhibition.
Unexpectedly, we did not observe any differences in PD-1+ expression on any T cell subsets 
and did not observe any difference in Foxp3+ regulatory T cells. This could have been 
because PD-1 is upregulated on antigen-specific T cells, and we were only able to quantify 
differences in the entire memory T cell population rather than the antigen-specific T cells in 
our patient samples. However, there are reports in the literature that PD-1, PD-L1, and T 
regulatory cell markers are decreased after cryopreservation of human PBMC,61,62 therefore 
it is possible that our negative finding is due to the limitations of our experimental protocol.
Our Luminex analysis revealed a systemic decrease in TNF-α as well as a decrease in 
multiple chemokines such as RANTES (CCL5) and IP-10 (CXCL10). RANTES plays a role 
in homing and migration of effector and memory T cells and helps sustain CD8 T cell 
responses during a systemic chronic viral infection,63 therefore it is possible that it is 
playing a similar role in anti-tumor immunity induced by SAR. IP-10 is IFN-γ-inducible 
protein 10, and is a chemoattractant for activated memory T cells and NK cells by binding to 
and activating CXCR3, 64 therefore it may play a role in T cell or NK cell homing after 
SAR. The systemic decrease in these cytokines is somewhat unexpected given the 
inflammatory nature of radiotherapy, but has been reported in other studies (Sridharan, 
2016). The clinical significance of these decreases and how they relate to changes which 
may be occurring in the tumor microenvironment is unclear. Future studies are needed to 
determine if this is due to the reduced half-life, increased degradation, or lower transcription 
and translation of these cytokines. Unexpectedly, we did not observe changes in the pro-
inflammatory cytokines IFN-α, IFN-γ or TGF-β which have been implicated in immune 
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response to radiation in other studies, perhaps because changes in these cytokines are short-
lived. 22, 23, 24, 65
There are several key limitations to our study, most significantly the inherent baseline 
differences in radiation dose, fractionation, and target volume size used to treat parenchymal 
sites vs. bony metastases and brain metastases based on the standard of care treatment for 
each disease site. It is possible the observed differences in immunophenotype may result 
from differences in dose and fractionation, rather than treated site. Spearman’s correlation 
coefficients suggest that greater total doses of ablative radiation are associated with an 
increase in the percentage of activated memory CD4+ and CD8+ T cells. The ablative doses 
used to irradiate each site are site-dependent, and higher total doses are typically used 
clinically for liver and lung tumors as compared to brain and bone tumors. Therefore, the 
observed differences in immune cell populations between sites could be due to the fact that 
parenchymal lesions are treated to a higher ablative dose than bone and brain lesions. We 
cannot analyze the contribution of these two variables separately because the study has a 
limited sample size, and all patients were treated according to the standard of care SAR 
protocols which allows for minimal variation in dose within each site. An additional 
limitation is that all of our analyses were performed on batched cryopreserved PBMCs, and 
there is data to suggest that some biomarkers may be altered in cryopreserved samples.61,62
In conclusion, we have identified changes in systemic immunophenotype after SAR to the 
lung and liver that we do not observe following SAR to the bone and brain. Our findings 
suggest SAR may be less immunomodulatory when directed to bone or brain, possibly 
because of the immunosuppressive environment in these organs. We cannot exclude the 
possibility that differences in the standard-of-care dose schemas for these organs contributed 
to the observed differences. Correlation between systemic immunophenotype changes and 
patient outcomes will be crucial to understand the clinical relevance of our finding and the 
potential for any of these changes to serve as biomarkers. Ultimately, our goal is to use this 
knowledge about the immune response following SAR to different sites to refine ongoing 
and future clinical studies combining SAR and immunotherapy.
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Figure 1: Decrease in the total and cytotoxic NK cells after SAR to parenchymal Sites, but not 
bone or brain.
A. Gating strategy for identification of Natural Killer cell subsets from total lymphocytes in 
PBMC. B. Total NK cells in PBMC after SAR to parenchymal sites, bone and brain. C. 
Cytotoxic NK cells in PBMC after SAR to parenchymal sites, bone and brain.
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Figure 2: Increase in TIM3+ NK cells after SAR to parenchymal sites.
Percent TIM3+ NK cells of the total NK cell population in PBMC after SAR to parenchymal 
sites (red), bone (blue), and brain (green).
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Figure 3: SAR causes increases in memory CD4+ and CD8+ T cell populations, including 
activated ICOS+ and CD25+ memory T cells.
A. Gating strategy for memory CD4+ T cell subsets and activated ICOS+ cells. B. Memory 
CD4+ T cell populations after SAR to parenchymal organs, bone, and brain. C. Activated 
ICOS+ CD4+ memory T cell population after SAR to parenchymal sites alone. D. Activated 
CD25+ Memory CD4+ T cell populations after SAR to parenchymal sites alone. E. 
Activated CD25+ memory CD8+ T cells after SAR to parenchymal sites alone.
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Figure 4: SAR causes an increase in the activated CD25+ memory CD8+ T cells.
A. Percent CD8+ memory T cells after SAR to parenchymal sites. B. Percent activated 
CD25+ memory CD8+ T cells after SAR to parenchymal sites.
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Figure 5: 
Luminex analysis of cytokines and chemokines in the serum of patients treated with SAR to 
parenchymal, bone, and brain sites. A. TNF-alpha. B. IL-10. C. MCP-1. D. MCP-2. E. 
MIP-1 alpha. F. RANTES. (All cytokine and chemokine concentrations are in pg/mL)
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Table 1:
Patient Characteristics
Parenchymal (lung and liver) n=26 Bone (n=9) Brain (n=5) p-value
Age Median (range) 71 (30−86) 64 (37−78) 66 (48−74) 0.13
PTV (cc) Median (range) 31.3 (5.5−277.8) 48.9 (11.5−174.1) 0.8 (0.6−2.1) 0.13
Disease Stage
 I 20 0 0
 II 1 0 0
 IV 5 9 5
Pack-year smoking Median (range) 13 (0−120) 0 (0−30) 15 (0−40) 0.17
Dose (Gy) Median (range) 50 (35−54) 24 (24−27) 21 (20−21) <0.00001
Number of fractions Median (range) 5 (3−5) 3 (3−3) 1 (1−1) <0.00001
Histology (%) 0.46
 Adenocarcinoma 12 (46%) 7 (78%) 2 (40%)
 Squamous 5 (19%) 0 1 (20%)
 Sarcoma 3 (12%) 0 0
 Undifferentiated/ other 3 (12%) 2 22%) 2 (40%)
 Unbiopsied 3 (12%) 0 0
Prior systemic therapy (% Yes) 38% 78% 60% 0.11
 Cytoxic chemotherapy 8 0 2
 Endocrine therapy 0 3 1
 Immunotherapy 0 1 1
 Targeted Therapy 2 3 0
Abbreviations: PTV = Planning Tumor Volume, Pack-years = number of pack-years of smoking cigarettes in the patient’s lifetime, Endocrine 
therapy = endocrine therapies for metastatic prostate cancer
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